Therapeutics News and Research

RSS
USPTO reaffirms the validity of ExonHit Therapeutics' SpliceArray patent

USPTO reaffirms the validity of ExonHit Therapeutics' SpliceArray patent

Gene therapy may help improve congenital blindness in children

Gene therapy may help improve congenital blindness in children

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Celgene announces fiscal 2009 third-quarter results

Celgene announces fiscal 2009 third-quarter results

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

FDA extends Acorda Therapeutics' Fampridine-SR  PDUFA goal date

FDA extends Acorda Therapeutics' Fampridine-SR PDUFA goal date

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Clinical performance study reveals the accuracy and precision of TRUE2go system

Clinical performance study reveals the accuracy and precision of TRUE2go system

France Biotech announces its 5th Bioethics Forum

France Biotech announces its 5th Bioethics Forum

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

FDA grants Fast Track designation for MacuSight's Perceiva

FDA grants Fast Track designation for MacuSight's Perceiva

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

BioWa, NKT Therapeutics sign licensing agreement

BioWa, NKT Therapeutics sign licensing agreement

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.